In a groundbreaking development that could redefine cancer treatment, researchers have achieved remarkable success using a novel gene therapy technique called base-editing to treat one of the most aggressive forms of childhood cancer. The therapy, known as BE-CAR7, has shown unprecedented results in treating T-cell acute lymphoblastic leukemia (T-ALL), a rare and often fatal blood cancer that had previously been considered virtually incurable in relapsed cases.
World’s First Base-Editing Gene Therapy
In 2022, a team of researchers at Great Ormond Street Hospital (GOSH) and University College London (UCL) made medical history by delivering the world’s first gene therapy created using base-editing technology to a 13-year-old girl named Alyssa Tapley from Leicester. Her case represented a turning point in the battle against T-ALL, demonstrating that an entirely new approach to gene therapy could yield extraordinary results where conventional treatments had failed.
Base-editing, a newer form of genome editing technology, differs significantly from traditional CRISPR-Cas9 methods by making precise chemical changes to DNA without cutting the double helix structure. This approach reduces the risk of unwanted genetic alterations and enhances safety, particularly important when treating pediatric patients. Unlike CRISPR-Cas9 that creates double-strand breaks in DNA which can lead to unintended mutations, base editors work by directly converting one DNA base to another, providing unprecedented precision in genetic modifications.
Clinical Trial Results and Patient Outcomes
Following the initial success with Alyssa, the therapy was expanded to treat a total of 11 patients—8 children and 2 adults—at GOSH and King’s College Hospital. The results, published in the New England Journal of Medicine and presented at the American Society of Hematology Annual Meeting in 2025, have been described as “remarkable” by the medical community.
Impressive Success Rates
The clinical trial demonstrated unprecedented efficacy with 82% of patients achieving very deep remissions. This enabled them to proceed to stem cell transplant without active disease—a critical milestone for patients with this aggressive form of leukemia. Most impressively, 63% of the patients who underwent the treatment remained disease-free and off all other therapy three years later, indicating durable and potentially curative responses.
These statistics represent a dramatic improvement over conventional treatments for relapsed T-ALL, where long-term survival rates typically hover around 10-20%. The ability to achieve both high remission rates and sustained disease-free survival marks a transformative advance in treating this challenging malignancy.
Addressing an Unmet Medical Need
T-ALL comprises approximately 10-15% of pediatric and 25% of adult acute lymphoblastic leukemia cases, making it one of the more aggressive forms of blood cancer. Standard treatments include intensive chemotherapy and bone marrow transplantation, but these approaches fail in roughly 20% of cases, leaving patients with few viable options. Developing CAR-T cell therapy for leukemia that itself originates from abnormal T-cells has historically been extremely challenging, as traditional approaches often resulted in the modified cells attacking each other or being rejected by the patient’s immune system.
How BE-CAR7 Works
The BE-CAR7 therapy represents a sophisticated application of base-editing technology to solve these challenges. The treatment involves engineering healthy donor T-cells through multiple precise genetic modifications:
- Modifying donor T-cells so they’re not attacked by the patient’s own immune system
- Removing a ‘flag’ that prevents the edited cells from attacking each other before treatment
- Making cells ‘invisible’ to other cancer treatments to prevent interference
- Adding mechanisms that enable recognition and destruction of cancerous T-cells
This multi-step engineering process creates what researchers call “ready-made” CAR-T cells that can be rapidly deployed in emergency situations. Once infused into patients, these edited CAR-T cells rapidly find and destroy both healthy and leukemic T-cells in the body. Following successful clearance of the leukemia, patients receive a bone marrow transplant to restore their depleted immune system.
Real-World Impact: Alyssa’s Story
Alyssa Tapley’s case illustrates the transformative potential of this therapy. Diagnosed with T-cell leukemia in May 2021 after months of what her family initially thought were routine colds and viruses, she did not respond to standard chemotherapy and bone marrow transplant treatments. Faced with the prospect of palliative care, her medical team offered her the experimental base-edited cell therapy as a last resort.
“I chose to take part in the research as I felt that, even if it didn’t work for me, it could help others,” Alyssa said. “Years later, we know it worked and I’m doing really well. I’ve done all those things that you’re supposed to do when you’re a teenager. I’ve gone sailing, spent time away from home doing my Duke of Edinburgh Award but even just going to school is something I dreamed of when I was ill.”
Now 16, Alyssa has been discharged to long-term follow-up and is pursuing her goal of becoming a research scientist to help develop the next breakthrough treatments for cancer patients.
Broader Implications for Gene Therapy
This success represents more than just a treatment for one rare form of leukemia—it signals a paradigm shift in how gene editing technologies might be applied to treat a wide range of genetic and acquired diseases. The ability to create “off-the-shelf” gene therapies using healthy donor cells could dramatically reduce treatment costs and waiting times compared to traditional personalized CAR-T approaches that require harvesting and modifying each patient’s own cells.
The research was led by Professor Waseem Qasim at UCL Great Ormond Street Institute of Child Health, supported by funding from the National Institute for Health and Care Research (NIHR), Wellcome, the Medical Research Council, and GOSH Charity. The team operates from the Zayed Centre for Research into Rare Disease in Children, a state-of-the-art facility made possible by a £60 million gift from Her Highness Sheikha Fatima bint Mubarak.
The implications extend beyond T-ALL treatment. Gene editing technologies like BE-CAR7 could revolutionize treatment for other blood cancers and potentially solid tumors, provided researchers can overcome the unique challenges each cancer type presents. The success has prompted GOSH Charity to commit an additional £2 million to treat another 10 patients, expanding access to this potentially life-saving therapy.
Looking Forward
While challenges remain, including managing side effects like low blood counts, cytokine release syndrome, and increased infection risk during immune recovery, the results establish base-editing as a viable and potentially superior approach to traditional gene editing methods. The therapy’s success in achieving both high remission rates and sustained disease-free survival offers genuine hope to families facing this devastating diagnosis.
As researchers continue to refine the technique and expand its applications, BE-CAR7 represents not just a treatment breakthrough but a glimpse into a future where previously incurable genetic diseases might be routinely treated with precision gene editing. For patients like Alyssa and the other children who have benefited from this therapy, that future is already here.
Sources
Great Ormond Street Hospital: ‘Ready-made’ T-cell gene therapy tackles ‘incurable’ T-Cell leukaemia
American Cancer Society: Acute Lymphoblastic Leukemia
Nature Reviews Disease Primers: Acute lymphoblastic leukaemia
Leave a Reply